New liver cancer treatment shows promise in early trial
NCT ID NCT02028949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a chemotherapy drug called idarubicin mixed with a contrast oil (lipiodol) injected directly into the liver artery for people with liver cancer that cannot be removed by surgery. The 15 participants all had cirrhosis. The goal was to find a safe dose and see if this approach could be effective without damaging the liver further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- idarubicin (Zavedos®) mixed with lipiodol
- What this could lead to
- If it works, this could offer a new treatment option for liver cancer patients who cannot have surgery, with less toxicity than standard chemoembolisation.
- What could go wrong
- This is a very early Phase 1 trial with only 15 people, so it is too small to prove effectiveness. The main goal is just to find a safe dose, and side effects are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILD A/B7 CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Dijon
Dijon, 21079 Cedex, France